Tick-Derived Therapeutic Molecules With Akari Therapeutics' Rachelle Jacques
Business Of Biotech · 43 minutes ·

Tick-Derived Therapeutic Molecules With Akari Therapeutics' Rachelle Jacques

Ticks are a scourge. They're vectors of multiple serious an debilitating diseases, and evolution has made them perfectly adept at attaching to their hosts—and potentially spreading those diseases virtually undetected— that ability owing to anti-inflammatory and anesthetic proteins in their saliva. But the emerging biotech Akari Therapeutics thinks there's a broad range of medicinal value in those proteins. They've painstakingly developed a recombinant version of one such tick saliva-derived protein, called nomacopan, and put it to work in phase 3 trials to treat rare but deadly severe hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). On this week's episode of the Business of Biotech, Akari President & CEO Rachelle Jacques tells us about the redeeming qualities of tick saliva and how her company is putting it to work.

Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Comments (0)

You Must Be Logged In To Comment

Similar podcasts

Therapeutic Interventions

Therapeutic Girlfriends

Mind Tap with Alternative Therapeutics

Cognitive Coherence with Ziara Walter Akari

Nervous Tick Podcast

Tick Boot Camp

No Approved Therapeutic Claims